

Index

a

- acid organocatalysts 189–192
- acyl migration reactions 246
- aldehydes
 - catalytic asymmetric alkylation of 223–224
 - dialkylzinc to aldehydes 219–223
 - diethylzinc addition to aldehydes 222
- alkenes 106, 116, 162
 - catalytic asymmetric iodofunctionalization of 230–232
- 2-amino-2'-hydroxy-1,1'-binaphthyl (NOBIN) 7, 10, 32, 108, 173, 174, 183, 185, 187, 188, 199, 201, 202
- anaplastic lymphoma kinase (ALK) inhibitor 319
- β -aryl elimination 156
- N*-arylindole lactams 154
- asymmetric organic synthesis 6–9, 173
- asymmetric oxidative coupling reaction 13, 162, 271–273, 279, 298
- asymmetric ring-opening/cross metathesis (AROM/CM) 187
- atropisomerism
 - modulate selectivity 320–323
 - sotorasib development 324
 - within drug discovery 323–326
- atropisomeric drugs
 - configuration assignment 309–310
 - pharmaceutical market 311–320
 - benzamides 318–319
 - biaryls and heterobiaryls 312–316
 - diaryl amines 317–318
 - diaryl ethers 316–317
 - macrocycles 319–320
 - rotational energy barrier 310–311
- atropisomerism 4, 6, 45, 237
 - advantages 237
 - asymmetric organic synthesis 6–9
 - axially chiral ligands and organocatalysts 10–13
 - drug discovery and development 13–16
 - dynamic axial chirality 309
 - natural product synthesis 13
- atropisomers 5
 - enantioselective synthesis of 6–7
 - multikilogram scales 310
- atroposelective synthesis, advancements and challenges 7
- axial chirality and atropisomerism 4–6
- axially chiral compounds
 - aromatic rings 21
 - 2-naphthols
 - oxidative cross-coupling 29–37
 - oxidative homocoupling 22–29
 - oxidative spirocyclization 38–40
- axially chiral ligands and organocatalysts 10–13, 201

b

- base organocatalysts 192–193
- Bayesian optimization (BO) 61
- benzamides 15, 95, 107, 181, 312, 318

- biaryl lactones 137
 - catalytic asymmetric reactions 139–145
 - via C–C and C–Si Bonds Cleavage 155–159
 - via C–I bond cleavage 145–153
 - via C–N and C–P Bonds Cleavage 153–155
 - via C–O and C–S Bonds Cleavage 159–161
 - via transient pentacyclic metal species 162–164
 - BINAMs, chiral ligands 185–187
 - 1,1'-binaphthalene-2,2'-diols (BINOLs) 45
 - 1,1'-bi-2-naphthols (BINOLs) 4, 173
 - ligands 219
 - (*S*)-(-)-1,1'-bi-2-naphthol (BINOL) 237
 - binaphthyl-based chiral diene ligands 180–182
 - binaphthyl-based chiral DMAP
 - catalyst design 240
 - catalyst synthesis 241–242
 - intermolecular acyl transfer reactions 247–260
 - intramolecular acyl transfer reactions 242–247
 - binaphthyl-based monocarboxylic acid
 - ligands 182–183
 - 1,1-binaphthyl-2,2-disulfonic acid (BINSAs) 178, 189
 - 1,1'-binaphthyl moiety 10, 24, 237, 238
 - BINOLs
 - chiral ligands
 - binaphthyl-based chiral diene ligands 180–182
 - binaphthyl-based monocarboxylic acid ligands 182–183
 - cyclopentadienyl ligands 180–181
 - oxazoline-containing ligands 179
 - oxidative coupling of phenols 179–180
 - phenanthroline or pyridine unit 183–185
 - phosphorus-containing ligands 174–177
 - REMB 177–178
 - salen ligands 178
 - sulfur-containing ligands 178–179
 - chiral organocatalysts 189
 - acid organocatalysts 189–192
 - base organocatalysts 192–193
 - dialkylzinc to aldehydes 219–223
 - diethylzinc addition to aldehydes 222
 - oxidative cross-coupling 29–37
 - oxidative homocoupling 22–29
 - BINOL-Zn system 219
 - 2,2'-bis(di-phenylphosphino)-1,1'-binaphthyls (BINAPs) 4, 173
 - 3,3-bis(3,5-difluoromethylphenyl)binaphthol 223
 - bis(2-oxo-3-oxazolidinyl)phosphinyl (BOP) 76
 - bisoranjidiol 282–284
 - (*S*)-bisoranjidiol 282–284
 - bond dissociation energy (BDE) 155
 - Bringmann's lactones 140, 153
 - Brønsted acid 10, 27, 91, 120, 143, 189–191, 198, 201, 237
 - catalyst 189
 - Bruton's tyrosine kinase (BTK) 321, 324
 - inhibitor 324
- C**
- catalyst design, advantages 240
 - catalytic asymmetric direct aldol reaction 226–230
 - catalytic asymmetric reactions 139–145, 178
 - C–C chemokine receptor type-IV (CCR-5) 323
 - chaetoglobulin A 288–292
 - chiral axis 5, 93, 122, 138, 267–270, 272–295, 297, 309
 - chirality, defined 3
 - chiral ligands
 - NOBINS 187–188
 - phosphorus-containing ligands 174–177

- chiral organocatalysts
 acid organocatalysts 189–192
 base organocatalysts 192–193
- chiral oxazolines 179
- chiral stationary phase (CSP) 130, 310, 324
- chiral vanadium catalysis
 hydroxycarbazoles
 hetero-coupling 50–54
 homo-coupling 47–50
- circularly polarized luminescence (CPL) 4, 58, 61
- colchicine 15, 311, 314, 315, 326
- copper-catalyzed asymmetric oxidative coupling
 bisoranjidiol 282–283
 nigerone 273–276
 perylenequinones 276–282
- Corey–Bakshi–Shibata catalyst 270
- cross-coupling reactions 6–8, 21, 30, 37, 41, 159, 162, 163
- Curtin–Hammett principle 70, 74
- Curtin–Hammett rule 84
- d**
- Danishefsky's diene 187, 219, 224
- density functional theory (DFT) 8, 72, 74, 76, 77, 83, 97, 98, 101, 145, 152, 230, 232, 243, 245, 247, 310
- desymmetrization, of achiral substrates 269
- desymmetrization reactions 118, 121, 253–255, 257
- 2,2'-diamino-1,1'-binaphthalenes (BINAMs) 4, 173, 185–187, 197–199, 201
- diaryl amines 128, 317–319
- diastereoselective oxidative coupling 278, 287
- Diels–Alder reaction 185, 186, 191, 219
 catalytic asymmetric 224–225
 3,3'-dibromobinaphthoxide-catalyzed hetero 224
 zinc-binaphthoxide 219, 220
- dimeric hydroxycarbazoles 47
- (-)-3-*exo*-dimethylaminoisobornenol [(-)-DAIB) 220
- N,N*-4-dimethyl-4-aminopyridine (DMAP) 13, 237
- dinuclear zinc-(*R,S,S*)-3,3'-bis(aminoimino)binaphthoxide (*di-Zn*) 232
- direct aldol reaction 178, 192, 226–230
 Zinc bisproline-substituted phenoxide catalyst 227
- dynamic kinetic asymmetric transformation (DYKAT) 162, 226
- dynamic kinetic resolution (DKR) 9, 13, 95, 101, 114, 115, 129, 137, 140, 143, 145, 147, 162, 239, 258–260, 270, 292
- e**
- enantioselective addition reaction 219–223
- enantioselective oxidative coupling 25, 45–47, 49, 179–181, 274, 281, 282
- enones, catalytic asymmetric epoxidation of 225–226
- f**
- focal adhesion kinase (FAK) inhibitor 319
- Friedel–Craft substitution 21
- g**
- Gong-type catalysts 287
- h**
- heterodehydrohelicenes 58
- hetero-Diels–Alder reaction 187, 191
- 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP) 62
- high-performance liquid chromatography (HPLC) 107, 130, 139, 144, 200, 310
- hydroxycarbazoles
 enantioselective oxidative coupling 48–49

hydroxycarbazoles (*contd.*)

hetero-coupling 50–55

homo-coupling 47–50

3-hydroxycarbazoles 52, 58–62

oxaza[7]dehydrohelicenes 58–62

4-hydroxycarbazoles, homo-coupling
48–49

α -hydroxy ketones 226, 228, 229

hypocrellin A 276, 279–281

i

imidodiphosphorimidate (IDPi) 191

intermolecular acyl transfer reactions

desymmetrization of alcohols

253–258

dynamic kinetic resolution 258–260

kinetic resolution of alcohols 247–253

International Union of Pure and Applied
Chemistry (IUPAC) 3–5

intramolecular acyl transfer reactions

O-to C acyl transfer reaction 242–247

inverse-electron-demand imino

Diels–Alder (IEDIDA) reaction

224, 225

k

kotanin 295–297

Kumada coupling 72, 79, 269

l

LaLi₃tris-(binaphthoxide) (LLB) 226

m

macrocycles 15, 312, 319–320

Mannich reaction 106, 189, 191, 192, 197

Mannich-type reaction 120, 178, 187,
189, 190, 194

Migita–Kosugi–Stille cross-coupling 241

molecular chirality 3–6

types of 3–4

Morita–Baylis–Hillman reaction 192,
197

Mukaiyama–Mannich reaction 191

multivariant axially chiral catalysts
(MACC) 183

n

2-naphthols

asymmetric aerobic oxidative coupling
23–24

asymmetric oxidative coupling methods
270

chiral diphosphine oxide iron

complexes 26–28

chiral iron-phosphate-catalyzed

oxidative coupling 25

Fe-salan-catalyzed oxidative

cross-coupling 30

intramolecular spirocyclization 39–40

iron-phosphate-catalyzed oxidative

coupling 26

iron-salan-catalyzed asymmetric

aerobic oxidation 24–25

oxaza[7]dehydrohelicenes 58

hetero-coupling of hydroxycarbazole
with 50

oxidative cross-coupling 29–37

oxidative homocoupling 22–29

oxidative spirocyclization 38–40

Ru-salen 1-catalyzed stereoselective
coupling 22–23

natural products via atroposelective
coupling

kotanin 295–297

phlegmacins 297

natural product synthesis 13, 267–298

Negishi coupling reactions 82, 267

neurokinin-I (NK-1) receptor 326

N-heterocyclic carbene (NHC) 80, 160,
187

nigerone

retrosynthetic analysis 274

structure of 273–274

N-iodonaphthalenimide (NIN)-I₂ system
232

N-iodosuccinimide (NIS) 162, 230

NK-1 inhibitors 325–326

NOBINs

chiral ligands 187–188

iron-catalyzed diastereoselective
synthesis 32

non-small cell lung cancer (NSCLC)
311, 312

nonlinear effect (NLE) 54

o

organocatalysts and chiral ligands 10,
173

oxa[9]helicenes via chiral vanadium
complex 55–58

oxaza[7]dehydrohelicenes via chiral
vanadium complex 58–62

p

perylenequinones 276–282

pharmaceutical market 311

benzamides 318–319

biaryls and heterobiaryls 312–316

diaryl ethers 316–317

macrocycles 319–320

phase-transfer catalysis (PTC) 9, 92,
112–120, 128

phlegmacins 297, 298

phosphoric acid catalysis (PAC) 9, 92,
121

PI3K β inhibitor 325, 326

Pictet–Spengler reaction 62

polycyclic heteroaromatics (PHAs) 8

chiral vanadium catalysis

hydroxycarbazoles, hetero-coupling
50–55

hydroxycarbazoles, homo-coupling
47–50

oxa[9]helicenes 55–58

oxaza[7]dehydrohelicenes 58–62

poly(methylhydrosiloxane) (PHMS) 140

Proline-rich tyrosine Kinase 2 (PyK2)
319

pyrrolopyrimidine (PPY) inhibitor 322

r

rare earth-alkali metal-BINOL (REMB)
177–178

receptor tyrosine kinase (RTK) 317

ring-opening reactions

biaryl lactones 137–145

catalytic asymmetric reactions
139–145

via C–C and C–Si bonds cleavage
155–159

via C–I bond cleavage 145–153

via C–N and C–P bonds cleavage
153–155

via C–O and C–S bonds cleavage
159–161

via transient pentacyclic metal
species 162–164

Ru-salen catalyzed aerobic oxidation 23

s

Shibasaki's catalytic asymmetric direct
aldol reactions 226

single-electron transfer (SET) 22, 26, 35,
54, 56

Sonogashira coupling 290, 291
reaction 291

sorazolon E2 49, 50, 288, 289

π – π stacking interaction 80

stereochemistry 3, 13, 158, 278, 279, 281,
282, 298, 317

sulfoxide dialkylphosphine ligands (SOPs)
152

supercritical fluid chromatography (SFC)
15, 310, 324, 326

Suzuki–Miyaura coupling (SMC) 8, 69

asymmetric cross-coupling

dependent directing group 74–79
earliest stages 72

independent directing group 79–84

cross coupling 281

mechanism insight of 70–72

reaction 267

C₂-symmetric catalysts 242

t

tert-butyl hydroperoxide (TBHP) 225

1,1,2,2-tetrachloroethane (TCE) 52

transition metal-mediated coupling
reaction 269

- transition state (TS) 10, 70, 91, 115, 121, 122, 127, 138, 237, 238, 240, 243, 245, 247, 248, 250–253, 285
- transmetalation (TM) 70
- Trost's Zn-catalyses 228
- U**
- Ullmann-type coupling reactions 268
- V**
- vanadium-catalyzed asymmetric oxidative coupling
- chaetoglobin A 288–291
 - gonytolide A 291–295
 - Sorazolone E2 288
 - viriditoxin 283–288
- vanadium-catalyzed oxidative coupling 272, 285, 288, 290, 291
- Vancomycin 314, 316
- Vancomycin B 314
- van der Waals radius (rvdW) 77
- variable temperature NMR (VT-NMR) 310
- Vilsmeier–Haack formylation 290, 291
- vinyllogous addition 292, 294
- viriditoxin 283–287
- Z**
- zinc binaphthoxide catalyst
- asymmetric activation 222
- zinc binaphthoxide system 222, 225
- Zn²⁺-dependent aldolases 229, 233